Gilead Sciences, Inc. 13D and 13G filings for Kalaris Therapeutics Inc:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-03-20 4:32 pm Purchase |
2025-03-18 | 13G | Kalaris Therapeutics Inc KLRS |
GILEAD SCIENCES INC. GILD |
723,273 3.900% |
723,273 (New Position) |
Filing |